Reuters logo
BRIEF-Neovacs syas phase IIb trial Ifnalpha Kinoid in Lupus gets positive IDSMB review
July 11, 2017 / 5:33 AM / 2 months ago

BRIEF-Neovacs syas phase IIb trial Ifnalpha Kinoid in Lupus gets positive IDSMB review

July 11 (Reuters) - NEOVACS SA

* REG-NEOVACS ANNOUNCES POSITIVE IDSMB REVIEW FOR PHASE IIB CLINICAL TRIAL OF IFNALPHA KINOID IN LUPUS

* ‍THIRD IDSMB DATA REVIEW OF ONGOING PHASE IIB CLINICAL TRIAL​

* ‍“ALL PATIENTS ARE NOW FOLLOWED DURING 9 MONTHS, AND OUR GOAL IS TO REPORT DATA IN Q2 2018.”​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below